Receives US Patent

8 Oct 2007 07:00

PuriCore Plc08 October 2007 PuriCore Receives US Patent on Wound Therapy Method Hypochlorous Acid Invention Shown to Enhance Wound Healing STAFFORD, UK, October 8, 2007-PuriCore (LSE: PURI), the life sciences companyfocused on the control of infectious pathogens, today announces that the USPatent and Trademark Office has granted US Patent No. 7,276,255, entitled Woundand Ulcer Treatment with Super-Oxidized Water relating to wound therapy methods.PuriCore's methods employ hypochlorous acid at neutral or near-neutral pH toenhance the healing process for wounds. Related patents have been approvedpreviously for PuriCore's technology in the UK and Europe. PuriCore's invention is broadly drawn to methods of treating any open wound withhypochlorous acid solutions at neutral or near-neutral pH including twoimportant processes, reducing wound bioburden and promoting tissue repair.Research data submitted with the patent shows that PuriCore's invention methodprovides an optimum wound-healing environment by decreasing the bioburden ofharmful microorganisms within the wound and by promoting skin cell proliferationand re-growth. Greg Bosch, CEO of PuriCore, said: "Our research indicates that hypochlorous acid solutions represent a new andeffective class of treatment for hard-to-heal wounds," "The granting of thisfirst US patent specific for wound therapy complements our broad intellectualproperty portfolio focused on antimicrobial solutions and devices for producingthese solutions." For further information please contact: PuriCore +1 (484) 321 2700 Keith Goldan Financial Dynamics +44 207 269 7169 Ben Brewerton / John Gilbert Notes to editors About PuriCore's Wound Therapy Solution PuriCore's patented wound therapy technology is being commercialized as theVashe(TM) Wound Therapy System, a novel, noninvasive, easy-to-use woundmanagement process that has been shown to be complementary to existing treatmentmethods. The Vashe System is an FDA-cleared medical device used for moistening,irrigating, cleaning, and debriding acute and chronic wounds including stage Ithrough IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgicalwounds, first and second degree burns, abrasions, and minor irritations of theskin. The Vashe Solution mimics the human body's own infection fighter,hypochlorous acid. Recent and ongoing clinical case studies show that the VasheSolution eliminates pathogens that produce harmful toxins and odor and causesignificant pain, without any damage to tissue. Research to date demonstratesthat the Vashe Solution provides a safe and effective alternative to cytotoxicantimicrobial and antiseptic products currently used to treat infected woundsand surgical sites and is an important element in the overall clinical processof effective wound management. About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercializing proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound therapy, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange